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Abstract
Background: Idiopathic or genetic adult-onset epilepsy is a common neurological disorder in domestic dogs. Genetic
association has been reported only with ADAM23 on CFA 37 in few breeds. To identify novel epilepsy genes, we
performed genome-wide association (GWA) analyses in four new breeds, and investigated the association of the
previously reported ADAM23 haplotype with the epilepsy phenotype in eight breeds.
Results: GWA analysis did not reveal new epilepsy loci. ADAM23 association (p < 0.05) was identified in five breeds.
Combined analysis of all eight breeds showed significant association (p = 4.6e−6, OR 1.9).
Conclusions: Our results further support the role of ADAM23 in multiple breeds as a common risk gene for epilepsy
with low penetrance. The lack of findings in the GWA analyses points towards inefficient capture of genetic variation
by the current SNP arrays, causal variant(s) with low penetrance and possible phenocopies. Future work will include
studies on ADAM23 function and expression in canine neurons, as well as whole-genome sequencing in order to
identify additional IE genes.
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Background
Idiopathic, or primarily genetic, epilepsy (IE) is the most
common neurological disease in dogs with an overall
prevalence of approximately 0.62% [1]. It is common
across many breeds, but some breeds have higher
disease prevalence, which indicates increased genetic
predisposition [1–7]. Although pedigree analysis has
clearly suggested strong genetic influence, the identifica-
tion of risk genes has been challenging [8].
To date, two genes underlying canine IE have been
identified: LGI2 on chromosome 3 for benign juvenile
epilepsy in the Lagotto Romagnolo breed [9], and
ADAM23 on chromosome 37 for focal and generalized
adult-onset epilepsy in the Belgian Shepherd breed [10].
According to our recent study employing high-density
genome-wide association (GWA) analysis and targeted
next generation sequencing in large sample cohorts,
ADAM23 harbors a common risk haplotype for IE in
Belgian Shepherd, Finnish Spitz, Schipperke and Beagle
breeds [11]. The risk haplotype spans exons 5 and 11 of
the ADAM23 gene and presented with odds ratios of
3.3–12.0 depending on the breed. The results suggest
that ADAM23 is a common but a low penetrance risk
gene for IE in several breeds, but other yet unknown
factors may contribute to the disease risk. ADAM23
(ADAM23 metallopeptidase domain 23) is a membrane-
anchored protein expressed in several tissues and
involved in cell adhesion and central nervous system
development. It interacts with LGI1, LGI2 and ADAM22
in synaptic transmission [12]. LGI1, LGI2 and ADAM22
have previously been implicated in epilepsy [9, 13, 14].
In this study, we aimed to identify new IE loci by GWA
analyses in four breeds: Finnish Lapphund, Kromfohrländer,
Miniature Pinscher and Pyrenean Shepherd. Furthermore,
we investigated the role of ADAM23 in an extended
epilepsy collection of altogether eight dog breeds with
IE: Australian Shepherd, Irish Setter, Labrador Retriever
and Whippet, and the above mentioned breeds.
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Methods
In order to identify genes underlying canine epilepsy, we
investigated the characteristics of IE in the studied breeds,
collected DNA samples from cases and controls with IE
and performed GWA analyses in four dog breeds. We also
studied the association of the ADAM23 gene with IE in
eight dog breeds.
Sample collection and phenotyping
Whole blood or buccal swab samples were collected
from privately-owned dogs with the owner’s consent
mainly from Finland but also some cases and controls
from France, Germany, Sweden and UK. The samples
were recruited through breed clubs, scientific collabo-
rators, veterinarians, and advertisement in various dog
fancier forums. The samples were stored at the Dog
DNA bank at the University of Helsinki along with the
dogs’ health and pedigree information. The selection
of suspected IE cases and controls was performed as
described previously [11]. The suspected diagnosis of
IE was based on a 10-page epilepsy questionnaire
available in multiple languages (www.koirangeenit.fi)
[15]. The healthy controls were not first or second
degree relatives to the cases or to other controls.
Genomic DNA was extracted from whole blood samples
and buccal swabs using the Puregene DNA Purification
Kit (Gentra Systems) and Chemagic Magnetic Separation
Module I (MSM I) (Chemagen Biopolymer-Technologie
AG, Baeswieler, Germany) according to the manufac-
turer’s instructions.
Clinical examination
Altogether, 24 Kromfohrländers (17 cases, 7 controls),
12 Finnish Lapphunds (9 cases, 3 controls) and 12
Pyrenean Shepherds (10 cases, 2 controls) were clinic-
ally studied at the Referral Animal Neurology Hospital
Aisti, Vantaa, Finland as described previously [7, 10].
The results of the clinical studies for Australian Shepherds
have been reported previously [15]. Clinical studies were
not performed for the other breeds.
Genome-wide association analyses
GWA analyses were conducted for four breeds: Finnish
Lapphunds, Kromfohrländers, Miniature Pinschers and
Pyrenean Shepherds. The number of samples in each
breed and genotyping platforms used are presented in
Table 1. The samples were genotyped either with the
Affymetrix Canine Genome 2.0 Array platinum set
(Affymetrix, Santa Clara, CA, USA) with ~50,000
single-nucleotide polymorphism (SNP) markers or
with the Illumina Canine HD Bead chips (Illumina,
Inc., San Diego, CA, USA) for more than 173,000 SNPs
across all canine chromosomes. The samples were
genotyped at the Centre National de Génotypage
(Paris, France) as part of the EU-funded LUPA project
[16]. The genotype data was analysed with GenABEL v.
1.6–7 [17] in R v. 2.13.0. The Affymetrix GWA data
was filtered for minor allele frequency > 0.05, genotype
call rate > 0.75, individual call rate > 0.75 and Hardy-
Weinberg equilibrium p > 0.0001. The Illumina GWA
data was filtered for minor allele frequency > 0.05,
genotype call rate > 0.95, individual call rate > 0.95 and
Hardy-Weinberg equilibrium p > 0.00001. Multidimen-
sional scaling plots were produced for each genotyped
breed to identify outliers and population stratification.
Identity-by-state values were calculated for each pairs
of individuals to control for duplicate samples and
relatedness. The GWA analyses were performed using
mixed model approach in GenABEL [17, 18]. The esti-
mation of polygenic model was performed using the
polygenic option in GenABEL [19]. If the genomic in-
flation factor λ was >1, the association p-values were
corrected for it. The quality control and association
analyses were performed separately for each breed.
ADAM23 haplotype analysis
To replicate the previous findings in CFA37, we esti-
mated the required sample size using the Genetic Power
Calculator [20]. The parameters for power calculation
derived from our previous article [10]. The statistical
power of our study materials were as follows: Australian
Shepherds 0.69, Finnish Lapphunds 0.55, Irish Setters
0.38, Kromfohrländers 0.43, Labrador Retrievers 0.47,
Miniature Pinschers 0.22, Pyrenean Shepherds 0.26 and
Whippets 0.27. The statistical power in the whole repli-
cation material was 0.99.
Six variants (4 SNPs and 2 indels) composing an
epilepsy risk haplotype according to our previous study
[11] were selected for genotyping. The genotyping was
performed using competitive allele-specific PCR (KASP)
assays [21] (LGC, Herts, UK) and ABI PRISM 7900HT Se-
quence Detection System instrument (Applied Biosystems,
Foster City, CA, USA) according to the protocols provided
by the manufacturers. The total call rate was 0.94, but only
0.83 in the Irish Setters. The SNPs were in Hardy-
Weinberg equilibrium (HWE) (p > 0.05) in the controls
except in the Labrador Retrievers the HWE p-values
were >0.01. The alleles and six-variant haplotypes were
analysed for association using PLINK v. 1.07 [22]. Com-
bined association analysis was performed using the
Cochran-Mantel-Haenzel-test to control for the differ-
ences between breed clusters. The associations for homo-
zygosity were calculated using the EpiTools package in R
(https://medepi.com/epitools/). Per individual per haplo-
type missingness of < 0.5 was required in the haplotype
analysis. The number of dogs included in this analysis is
given in Table 2.
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Results
Epilepsy phenotypes
The main characteristics of IE of the Finnish Lapphund,
Irish Setter, Kromfohrländer, Labrador Retriever, Miniature
Pinscher, Pyrenean Shepherd and Whippet cohorts were
collected through detailed questionnaires, and are pre-
sented in Additional file 1: Table S1. IE in the seven breeds
show typical onset at early adulthood, on average at the age
of 2–4.5 years (range 4 months–8 years), and manifest with
both focal and generalised seizures. A high variability in the
seizure frequency is present in all breeds ranging from one
reported episode in 2 years to several episodes per month.
The characteristics of epilepsy of Australian Shepherds have
been reported previously [15]. Besides questionnaire-based
survey of the seizure history, clinical examinations
were performed in selected dogs representing three
breeds (Kromfohrländers, Finnish Lapphunds, Pyrenean
Shepherds) to exclude possible external causes of seizures.
None of the exams revealed abnormalities in the cases or
controls, thereby supporting the diagnosis of IE or genetic
epilepsy in those breeds.
Genome wide association results
In order to identify loci underlying canine IE, GWA ana-
lyses were performed in altogether four dog breeds: Finnish
Lapphunds, Kromfohrländers, Miniature Pinschers and
Pyrenean Shepherds. No associations were identified in any
of the studied cohorts (Additional file 2: Figure S1).
Replication of the ADAM23 association
Single-variant association analyses showed association
(p < 0.05) in multiple breeds in ADAM23 (Additional file
3: Table S2) with odds ratios ranging between 1.7 and
12.3 depending on the breed. The epilepsy-risk conferring
alleles identified in our previous study were the major alleles
in all the breeds, and they were more common among cases
than controls in all breeds except for Finnish Lapphunds. A
combined analysis of all breeds showed strong statistical
significance (p= value 4.6e−6, OR 1.9, 95% CI 1.44–2.5 at
15,108,593 bp (genome build CanFam3.1). Combined
analysis without Finnish Lapphunds showed the highest
statistical significance of p = 2.5e−8 (OR 2.4, 95% CI 1.8–
3.3) at 15,108,593 bp. Association analysis combining all
Table 2 Association results of epilepsy and the ADAM23 risk haplotypea in eight dog breeds
Breed
N cases/controls
Risk haplo
cases freq
Risk haplo
control
freq
p-value OR (95% C.I.) Risk haplo
homozygosity
cases freq
Risk haplo
homozygosity
controls freq
p-value OR (95% C.I.) Cases/controls
without risk
haplotype
Australian Shepherd 59/71 0.66 0.52 0.03 1.8 (1.1–3.0) 0.46 0.32 0.11 1.8 (0.9–3.6) 14%/28%
Finnish Lapphund 35/50 0.46 0.50 0.58 0.8 (0.5–1.6) na na na na na
Irish Setter (red) 19/36 0.97 0.90 0.17 4.0 (0.5–33.7) 0.95 0.83 0.22 3.6 (0.4–32.4) 0%/3%
Kromfohrländer 46/29 0.88 0.69 0.004 3.2 (1.4–7.7) 0.83 0.45 0.0008 5.5 (1.9–16.8) 7%/7%
Labrador Retriever 29/50 0.59 0.33 0.003 2.9 (1.5–5.6) 0.34 0.16 0.06 2.8 (0.9–8.1) 17%/50%
Miniature Pinscher 16/15 0.88 0.7 0.05 3.3 (0.9–14.0) 0.75 0.53 0.21 2.5 (0.5–13.0) 0%/13%
Pyrenean Shepherd 17/23 0.65 0.43 0.06 2.3 (0.9–6.0) 0.47 0.13 0.02 5.5 (1.2–31.8) 18%/26%
Whippet 17/25 0.94 0.58 0.0002 11.3 (2.9–81.5) 0.89 0.36 0.0005 12.6 (2.7–102.3) 0%/20%
P-values <0.05 are bolded
OR odds ratio, C.I. confidence interval, na not analysed
aHaplotype T-C-del-del-G-G at 15,085,438 (BICF2S23030950), 15,106,446 (BICF2P1021781), 15,108,593, 15,108,802, 15,111,724 (BICF2P1131874) and 15,113,325 bp in
ADAM23 (~28 kb), respectively (CanFam3.1)
Table 1 Sample numbers, GWA platforms and sample origin
GWA ADAM23 SNP genotyping
Breed N cases N controls Sample origina Platform N cases N controls Sample origin
Australian Shepherd na na na na 61 75 GER, FIN
Finnish Lapphund 40 97 FIN, SWE Illumina 170 K 42 53 FIN, SWE
Irish Setter (red) na na na na 22 46 FIN, UK
Kromfohrländer 21 21 FIN Affymetrix 50 K 46 29 FIN
Labrador Retriever na na na na 32 52 FIN, GER
Miniature Pinscher 15 15 FIN Affymetrix 50 K 16 15 FIN
Pyrenean Shepherd 20 27 FIN,FRA Illumina 170 K 18 23 FIN, FRA
Whippet na na na na 17 25 FIN, GER
Total 96 160 254 318
GWA genome-wide association; na: not available, aSamples are mainly collected in these countries, FIN: Finland; FRA: France; GER: Germany; SWE: Sweden, UK:
United Kingdom
Koskinen et al. BMC Genetics  (2017) 18:8 Page 3 of 5
associated breeds from our previous [11] and current
studies yielded the highest statistical significance of p =
4.1e−18 (OR 2.6, 95% CI 2.1–3.2) at 15,108,593 bp.
The six-variant risk haplotype identified in our previous
study [11] consisted of variants T-C-del-del-G-G at
15,085,438 (BICF2S23030950), 15,106,446 (BICF2P1021781),
15,108,593, 15,108,802, 15,111,724 (BICF2P1131874) and
15,113,325 bp in ADAM23 (~28 kb), respectively
(CanFam3.1). This haplotype showed association (p < 0.05)
with IE in Australian Shepherds, Kromfohrländers, Labrador
Retrievers, and Whippets (Table 2). The haplotype frequen-
cies in Pyrenean Shepherds, Miniature Pinschers and Irish
Setters showed a similar trend as in the other studied
breeds, although the associations were not statistically sig-
nificant. The ADAM23 risk haplotype showed no evidence
of association with IE in the Finnish Lapphund cohort.
Discussion
In this study, we performed GWA analyses to four dog
breeds with IE in order to identify novel breed-specific
high-risk loci for the disease. As we previously reported that
ADAM23 is an important risk gene for canine IE [10, 11],
we also investigated whether ADAM23 plays a role in IE in
an extended epilepsy collection, which consisted of eight
additional dog breeds, and altogether 573 samples.
Most common human epilepsies are thought to have
complex inheritance determined by multiple susceptibility
loci with or without an environmental effect [23, 24]. Our
study strongly suggests that the genetic background of
common adult-onset IE does not follow simple Mendelian
inheritance pattern in a number of dog breeds. The lack of
association findings in the GWA studies performed in four
breeds, Finnish Lapphund, Kromfohrländer, Miniature
Pinscher and Pyrenean Shepherd, indicates inadequate
statistical power, which points towards perhaps a more
complex genetic background of the disease. There is
ample evidence in canine genetics, that our sample co-
horts were sufficient for the detection of loci harbour-
ing causative genes for Mendelian disorders with high
penetrance and without or with only few phenocopies
[9]. Also, the SNP arrays may not efficiently capture all
genetic variation in at least some of the studied breeds
and this may be one of the reasons for the failure to
find associations [11]. For example, the best associated
marker BICF2P890779 in the first study [10] does not
tag the locus in all breeds. The marker associated with
IE in Belgian Shepherds, Whippets and Kromfohrländers,
but not in Schipperke and Finnish Spitz. However, the
new six-SNP haplotype, identified by targeted resequen-
cing, shows association in all these breeds. Other non-
ADAM23-linked risk loci possibly exist for canine IE,
but their identification will require collection of extensive
sample cohorts with rigorous phenotyping as well as
denser marker maps or high-throughput sequencing.
In this study, we further confirmed ADAM23 as a risk
gene for canine IE. Although statistical power was lim-
ited in many breed cohorts, associations were identified
in several breeds: Australian Shepherd, Kromfohrländer,
Labrador Retriever, Pyrenean Shepherd, and Whippet.
Finnish Lapphund was the only breed, which did not show
any evidence of association despite adequate statistical
power. This indicates either that ADAM23 does not play a
role in IE risk in this particular breed, or that the linkage
disequilibrium pattern at the ADAM23 locus differs in
Finnish Lapphunds compared to the other studied breeds.
Indeed, we may not yet have identified the causal variant in
ADAM23, as the almost 90% GC content of its 5’ end has
prevented us from investigating variation in ADAM23 pro-
moter region. The six variants composing the previously
identified IE risk haplotype are located between exons 5
and 11 in ADAM23, at least 88 kb away from the 5’ end.
Thus far, ADAM23 remains the only confirmed risk
gene for the common IE in dogs, and we now have evi-
dence for its role in IE in altogether 11 breeds. The iden-
tification of the causative variant at this locus will be
included in our future experiments. In addition, we will
investigate the function of ADAM23 in canine neurons
in order to improve the understanding of the aetiology
of canine IE. Our future experiments will also include
whole-genome and whole-exome analyses of IE-affected
dogs in order to identify novel genes for canine IE.
Conclusions
Idiopathic epilepsy is the most common neurological
disorder in dogs. Genetic cause for the disease has been
suspected in many breeds based on high disease preva-
lence and pedigree analyses. However, only few disease
genes have been identified to date. Our results further
support the role of ADAM23 in multiple dog breeds as a
common risk gene for epilepsy with low penetrance. The
lack of findings in the GWA analyses points towards
inefficient capture of genetic variation by the current
SNP arrays, causal variant(s) with low penetrance and
possible phenocopies. Our results warrant studies on
ADAM23 function and expression in canine neurons to
improve the understanding of the molecular pathogenesis
of common canine epilepsy.
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Additional file 1: Table S1. Summary of the epilepsy questionnaires.
(XLSX 13 kb)
Additional file 2: Figure S1. Genome-wide association study results. The
multidimensional scaling plots (i), quantile-quantile plots (ii) and Manhattan
plots (iii) are presented for Finnish Lapphunds (A), Kromfohrländers (B), Miniature
Pinschers (C) and Pyrenean Shepherds (D). In the multidimensional
scaling plots, red circles denote cases and blue controls. (TIF 1000 kb)
Additional file 3: Table S2. Allelic association results of the ADAM23
variants. (XLSX 16 kb)
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